Drug Profile
Research programme: haemophilia A gene therapeutics - Expression Therapeutics
Alternative Names: ET3 gene therapy - Opus Bio/Expression Therapeutics; LG 888Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Lentigen Corporation
- Developer Expression Therapeutics
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Blood coagulation factor replacements; Factor VIII stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Haemophilia-A in USA (IV, Infusion)
- 09 Oct 2020 Expression Therapeutics plans a phase I trial for Haemophilia in USA (SC, Injection) (NCT04418414)
- 26 May 2020 Preclinical studies are still underway in USA for Haemophilia A